India business to continue outperforming IPM
Management expects India revenue growth to remain above the IPM growth rate, driven by volume outperformance in chronic therapies.
TORRENTPHARMACEUTICALS / guidance tracker
Keep management guidance in view.
Torrent Pharmaceuticals · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
US revenue to cross $200 million annually next year
Management targets US annual revenue exceeding $200 million in FY27, driven by 5-7 new launches per year.
JB Pharma cost synergies of ₹400-450 crore over 2-3 years
Cost synergies from JB acquisition expected to be ₹400-450 crore, with ~20% in first year, up to 80% in second year, and rest in third.
Brazil growth target of 10-15% over next 2-3 years
Brazil business expected to grow 10-15% driven by new product launches and moderate price increases.